Aquestive Therapeutics Inc. (AQST) Misses Q1 EPS by 9c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AQST Hot Sheet
Join SI Premium – FREE
Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q1 EPS of ($0.17), $0.09 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $12.05 million versus the consensus estimate of $12.46 million.
GUIDANCE:
Aquestive Therapeutics Inc. sees FY2024 revenue of $48-51 million, versus the consensus of $50.1 million.
For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Host Hotels & Resorts (HST) Tops Q3 EPS by 1c; offers guidance
- Figma (FIG) Tops Q3 EPS by 5c, Offers Guidance
- Cognex Corp (CGNX) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
